Answers to CME examination

Answers to CME examination

Journal of the American Academy of Dermatology November 1994 Koff and Rosen 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. healing response by irnmuno...

101KB Sizes 0 Downloads 57 Views

Journal of the American Academy of Dermatology November 1994

Koff and Rosen

92.

93. 94. 95. 96. 97.

98. 99. 100. 101.

healing response by irnmunostimulant therapy (levamisole) in cutaneous leishmaniasis. Chemioterapia 1987; 6:214-6. Marsden PD, Cuba ec, Barreto AC, et a1. Nifurtimox in the treatment of South American leishmaniasis.Trans R Soc Trop Med Hyg 1979;73:391-4. Costa JM, Sampaio RN, Tada MS, et al, Furazolidone treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1985;79:274. Convit J, Castellanos PL, Ulrich M. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J Infect Dis 1989;160:104-15. Modabber F. Development of vaccinesagainstleishmaniasis, Scand J Infect Dis 1990;76:S72-S78. Modabber F. Experienceswith vaccinesagainst cutaneous leishmaniasis:ofmen and mice. Parasitology1989;98:S49S60. van Ek B, Dijkmans BA, van Dulken H, et a1. Immunotherapy as treatment of cutaneous leishmaniasis. J Infect Dis 1991;164:1244-5. Badaro R, Johnson WD. The role of interferon-gamma in the treatment of visceral and diffusecutaneous leishmaniasis. J Infect Dis 1993;167:S13-817. Botasso 0, Cabrini J, Falcoff R. Successful treatment of an antimony-resistant American mucocutaneousleishmaniasis: a case report. Arch DermatoI1992;128:996-7. Kurkcuoglu N, Tandogdu R. Interferon gamma therapy for cutaneous leishmaniasis. Arch Dermatol 1990; 126:831-2. Harms G, Chehade AK, Douba M, et al. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of

cutaneous leishmaniasis. Trans R Soc Trop Moo Hyg 1991;85:214-6. 102. Harms G, Chehade AK, Racz P, et aI. Effects of intradermal gamma-interferon in cutaneous leishmaniasis.Lancet 1989;1:1287-92. 103. AkuffoH, KaplanG, Kiessling R, et a1. Administrationof recombinant interleukin-2 reduces the parasite load of patients withdisseminated cutaneousleishmaniasis. J Infect Dis 1990;161:775-80. 104. Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicityof sodiumstibogluconate for mucosalleishmaniasis, Ann Intern Moo 1990;113:934-40. 105. Antezana G, Zeballos R, Mendoza C, et a1. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Trans R Soc Trop Moo Hyg 1992;86:31-3. 106. Herwaldt BL, Kaye BT, Lepore TJ, et a1. Sodium stibogluconate (Pentostam) overdose during treatment of American cutaneous leishmaniasis. J Infect Dis 1992; 165:968-71. 107. Balzan M, FenechF. Acute renal failure in visceral leishmaniasistreated withsodiumstibogluconate. Trans R Soc Trop Med Hyg 1992;86:515-6. 108. Lang PG Jr. Sulfones and sulfonamides in dermatology today. J AM ACAD DERMATOL 1979;1:479-92. 109. Sands M, Kron MA, Brown RB. Pentamidine: a review. Rev Infect Dis 1985;7:625-34. 110. Ramesh V,Saxena U, Misra RS. Efficacyofketoconazole in post-kala-azar dermal leishmaniasis. Arch Dermatol 1992;128:411-2. 111. Kalter DC. Laboratory tests for the diagnosis and evaluation of leishmaniasis. Dermatol Clin 1994;12:37-49.

Answers to CME examination*

Identification No. 894-110

October 1994 issue of the JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Questions 1-33, von den Driesch P. JAM

ACAD DERMATOL

1. c (p 536, c 2, pa 1) (p 537, c 1, pa 3) (p 546, c 2, pa 4)

2. b 3. a 4. e 5. a

(p 535, Abstract) (p 537, c 2, pa 3) 6. d (p 538, c 1, pa 1)

7. a (p 542, c 2, pa 2) 8. a (p 542, c 2, pa 2; p 543, c 2, pa 2; p 544, c 2, pa 3) 9. a (p 544, c 1, pa 2) 10. b (p 539, c I, pa 8) 11. b (p 539, c 1, pa 8; P 544, C 1, pa 2; p 542, C 1, pa 1; P 542, C 1, pa 2) 12. a (p 542, C 1, pa 3 and Ta III) 13. d (p 545, C 1, pa 2; p 545, c 2, pa 1) 14. e (p 544, c 2, pa 6; p 545, C 1, pa 1; p 545, C 1, pa 2; p 545, C 1, pa 3; P 546, C 1, pa 1) 15. e (p 543, Ta IV) 16. a (p 546, C 2, pa 2; p 546, Ta VII) *p: page; c: column; pa: paragraph; Ta: Table.

708

1994;31:535-56.

17. e (p 545, Ta VI) C (p 546, c 2, pa 3; p 19. e (p 547, C 1, pa 1; p 20. b (p 539, C 1, pa 8; P 21. C (p 539, c 2, pa 1; p pa 3) 22. e (p 543, Ta IV) 23. b (p 544, c 2, pa 1) 24. a (p 539, C 2, pa 1) 25. c (p 543, Ta IV) 26. e (p 543, Ta IV) 27. d (p 543, Ta IV) 28. b (p 548, Ta X) 29. a (p 548, Ta X) 30. C (p 548, Ta X) 31. a (p 548, Ta X) 32. e (p 547, C 1, pa 2) 33. d (p 548, Ta X) 18.

546, C 544, c 539, C 540, C

2, pa 4) 1, pa 4) 2, pa 1) 1, pa 2; p 545, c 1,